SNDX(Syndax Pharmaceuticals, Inc.) · 财务报表

SNDX(Syndax Pharmaceuticals, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$139.71M$0$0$23.68M$172.35M
毛利润—————
营业利润$26.22M−$151.76M−$229.95M−$339.67M−$273.08M
净利润$24.93M−$149.34M−$209.36M−$318.76M−$285.42M
经营现金流$29.13M−$133.68M−$160.60M−$274.90M−$322.98M
自由现金流$29.00M−$133.68M−$160.60M−$274.90M−$323.17M
摊薄每股收益$0.46$-2.46$-2.98$-3.72$-3.29

Syndax Pharmaceuticals, Inc. SNDX